Metformin and Dapagliflozin Decrease Fetuin A, Hepatic & Pancreatic Fat and Hepatic Fibrosis in Asian Indians with Type 2 diabetes

Abstract

Abstract Background and Objective: We intended to evaluate the effect of Metformin intervention for 120 days on hepatic and pancreatic fat, hepatic fibrosis, and Metformin and dapagliflozin (DAPA), fetuin A levels in patients with type 2 diabetes (T2D). Methods: This is a prospective study. Patients (n, 15) were given 1000mg of metformin/day and DAPA for a period of 120 days. Changes in anthropometry, surrogate markers of insulin resistance, body composition, fibroscan, liver, and pancreatic fat and serum fetuin-A were evaluated. Fibrosis-4 index (FIB) for liver fibrosis and hepatic steatosis index (HSI) was calculated. Results: After 120 days of treatment with Metformin and DAPA, a significant reduction in body weight, body mass index (BMI), %body fat, waist and hip circumferences, and total skinfold thickness was seen. A significant reduction in fetuin-A was seen with both Metformin and DAPA treatment, previously not reported for latter drug. Metformin significantly decreased CAP and kPa (fibroscan) but did not decrease hepatic and pancreatic fat (MRI-PDFF). Furthermore, FIB-4 and HIS scores were significantly decreased after 120 days of treatment with Metformin. Conclusions: Metformin and DAPA, after 120 days of use, reduced Fetuin A levels, and Metformin decreased FIB-4, HIS score, hepatic fibrosis but not hepatic and pancreatic fat in Asian Indian patients with T2D. Clinical Trial Number: Clinical Trials.gov: NCT05939921 (11/07/2023).